Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01243151 · ClinicalTrials.gov registry record · Phase 1

Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

A Phase 1 study of Hypercholesterolemia and Dyslipidemia, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
68
Enrollment target
9
Study locations

NCT01243151 is a Phase 1 study of Hypercholesterolemia and Dyslipidemia that has completed, run by Pfizer. The registered enrollment target is 68 participants, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (92% lower). The trial reports 9 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01243151, a Phase 1 study of Hypercholesterolemia and Dyslipidemia, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
68 participants
Enrollment target
9
Study locations

Study Summary

The primary objective of this study is to evaluate the safety and tolerability of repeated doses of PF-04950615 (RN316) in study volunteers with hypercholesterolemia. PF-04950615 is an investigational drug that is currently being studied as a lipid lowering agent.

Interventions

  • BIOLOGICAL PF-04950615 (RN316)

Study Locations (9)

California

  • California Clinical Trials Medical Group - Culver City
  • Glendale Adventist Medical Center - Glendale

Florida

  • SeaView Research, Inc. - Miami
  • SeaView Research, Inc. - Miami

Kansas

  • Vince and Associates Clinical Research - Overland Park
  • Vince and Associates Clinical Research - Overland Park

Hawaii

  • Covance Clinical Research Unit, Inc. - Honolulu

Minnesota

  • Prism Research - Saint Paul

Texas

  • Healthcare Discoveries, LLC dba ICON Development Solutions - San Antonio

Trial Details

FieldValue
Enrollment Target 68 participants
Start Date 2011-02
Est. Completion 2011-10
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT01243151

The ClinicalTrials.gov registry entry for NCT01243151 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (92% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hypercholesterolemia appearing as the primary indexed condition, and to 1 intervention - of which PF-04950615 (RN316) is the first listed.

NCT01243151 reports 9 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Kansas.

Frequently Asked Questions

What is clinical trial NCT01243151 about?

NCT01243151 is a clinical study titled "Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia". The primary objective of this study is to evaluate the safety and tolerability of repeated doses of PF-04950615 (RN316) in study volunteers with hypercholesterolemia. PF-04950615 is an investigational drug that is currently being studied as a lipid lowering agent.

What is the current status of trial NCT01243151?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2011-02. Estimated completion is 2011-10.

What conditions does trial NCT01243151 study?

This clinical trial studies the following conditions: Hypercholesterolemia, Dyslipidemia.

What interventions are being tested in trial NCT01243151?

The interventions under investigation include: PF-04950615 (RN316) (BIOLOGICAL).

Who is sponsoring clinical trial NCT01243151?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01243151 being conducted?

This trial has 9 study locations across California, Florida, Hawaii, Kansas, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypercholesterolemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.